Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRINOX in unresectable locally advanced and borderline resectable pancreatic cancer
NCT01688336Phase 2Terminated
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Jan 2012
- Primary completion
- Aug 2016
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of oxaliplatin, folinic acid, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab and fluorouracil in pancreatic adenocarcinoma (PDAC), sponsored by UNC Lineberger Comprehensive Cancer Center. Started Jan 2012; status: terminated.
02
Drugs
oxaliplatinfolinic acidirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabfluorouracil
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01688336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01688336.